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Abstract
Background: Mesothelioma is a highly malignant tumor that is primarily caused by occupational or environmental exposure
to asbestos fibers. Despite worldwide restrictions on asbestos usage, further cases are expected as diagnosis is typically 20–
40 years after exposure. Once diagnosed there is a very poor prognosis with a median survival rate of 9 months. Considering
this the development of early pre clinical diagnostic markers may help improve clinical outcomes.
Methodology: Microarray expression arrays on mesothelium and other tissues dissected from mice were used to identify
candidate mesothelial lineage markers. Candidates were further tested by qRTPCR and in-situ hybridization across a mouse
tissue panel. Two candidate biomarkers with the potential for secretion, uroplakin 3B (UPK3B), and leucine rich repeat
neuronal 4 (LRRN4) and one commercialized mesothelioma marker, mesothelin (MSLN) were then chosen for validation
across a panel of normal human primary cells, 16 established mesothelioma cell lines, 10 lung cancer lines, and a further set
of 8 unrelated cancer cell lines.
Conclusions: Within the primary cell panel, LRRN4 was only detected in primary mesothelial cells, but MSLN and UPK3B
were also detected in other cell types. MSLN was detected in bronchial epithelial cells and alveolar epithelial cells and
UPK3B was detected in retinal pigment epithelial cells and urothelial cells. Testing the cell line panel, MSLN was detected in
15 of the 16 mesothelioma cells lines, whereas LRRN4 was only detected in 8 and UPK3B in 6. Interestingly MSLN levels
appear to be upregulated in the mesothelioma lines compared to the primary mesothelial cells, while LRRN4 and UPK3B, are
either lost or down-regulated. Despite the higher fraction of mesothelioma lines positive for MSLN, it was also detected at
high levels in 2 lung cancer lines and 3 other unrelated cancer lines derived from papillotubular adenocarcinoma, signet ring
carcinoma and transitional cell carcinoma.
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Introduction
Mesothelioma is one of the most fatal and difficult to treat
cancers in the world and in Japan the median survival rate from
diagnosis is 9 months with 94% of patients not surviving at 3 years
[1]. In recent years the incidence of diagnosed cases of
mesothelioma in Japan has doubled from 500 cases in 1995 to
1068 in 2007. The majority of mesothelioma cases can be directly
linked to asbestos exposure and is estimated to be responsible for at
least 90% of all cases [2]. Asbestos has long been used for its
insulating properties and was used for insulation around pipes,
inside ceiling cavities, brake linings and compounded into asbestos
composite sheeting for an inexpensive heat and fire resistant
building material. In the 1960s it was recognized that occupational
asbestos exposure was a strong risk factor for the development of
mesothelioma [3,4,5]. At particular risk were asbestos mine
workers at locations such as Wittenoom Western Australia [6]
and Western Cape South Africa [5]. The realization that Asbestos
exposure was responsible led to legislation in multiple countries
which progressively reduced the use of asbestos and potential
exposure and finally led to complete bans in 52 countries [7].
Despite this, the past large scale use of asbestos means that there is
still a large amount of it in the general community that needs to be
safely removed, with demolition workers likely to be at risk. The
latent period between exposure and diagnosis is in the order of 20–
40 years meaning that workers who were exposed a long time ago
may still develop the disease [8]. Considering these two factors, the
number of mesothelioma cases is likely to continue to rise at least
for the next 20 years.
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25391For definitive diagnosis, immunohistochemical staining of
biopsy material for epithelial cell adhesion molecule (EPCAM)
and Vimentin (VIM) have been used to discriminate mesothelioma
from other lung cancers [9,10], however more recently a
microRNA based test with a higher accuracy has been developed
and made available to doctors [11]. These are important for
determining treatment however none of these are used for early
detection. Recently a kit (MESOMARK [12,13]) for detection of
soluble mesothelin related peptides in patients’ blood has made it
to market. This ELISA based kit is currently the most specific and
sensitive to market [14]. Mesothelin was originally identified as
megakaryocyte potentiating factor (MPF), and later termed
mesothelin when it was shown that an antibody against it reacted
with ovarian cancers and malignant melanomas [15,16] and as
early as 1999 it was shown that mesothelin related peptides could
be detected in the serum of ovarian cancer patients [17].
Mesothelin is produced as a transmembrane protein which is
then cleaved to release (MPF). Considering the poor prognosis and
the long latent period before diagnosis there is both a need for
earlier diagnosis and a real opportunity to develop earlier tests
(10–20 years window). In general earlier diagnosis means
improved likelihood of survival [18].
With this in mind we set out to identify additional mesothelial
lineage markers using a comparative functional genomics
approach. Gene expression profiling of dissected mouse mesothe-
lium and other tissues was used to identify candidate biomarkers
enriched in mesothelium. We then went on to filter these lists by
first focusing on candidate biomarkers that were likely to be
secreted or transmembrane proteins and then validating the
specificity of the markers by quantitative in-situ hybridization in
mouse tissues and real time PCR (qRTPCR) across a panel of
human cancer cell lines and normal lung cells and mesothelial cell
RNAs.
Materials and Methods
Ethics Statement
All animal work was carried out according to institutional and
national ethical guidelines, and approved by the Yokohama
Animal Experiment Review Committee, Plan19-002. Similarly all
human work was carried out according to institutional and
national ethical guidelines. The human mesothelioma sample used
in the immunohistochemistry was made available anonymously
from the autopsy material collection at the Department of
Pathology and Oncology, Juntendo University School of Medi-
cine. The human primary mesothelial cells were purchased from
Zenbio. The human primary cells were purchased from Zenbio,
Sciencell, Cell Applications and Lonza.
Animal and Tissue sources
The tissues of 7-week-old male mice on C57BL/6 backgrounds
were used for RNA preparation and for ISH. For RNA
preparation, mice were anesthetized, then sacrified, then their
organs were removed or harvested and immediately washed with
Phosphate-Buffered Saline (Invitrogen) and transferred into RNA
later (Ambion). Two sets of mesothelial tissue were prepared from
200 mice. Peritoneal mesothelium was prepared as one source and
pleural and pericardial mesothelium were pooled as the second
source. Lung, liver, brain, heart, skeletal muscle, subcutaneous
adipose, testis, bladder and kidney tissues were also dissected as
required for RNA extraction.
For ISH, Mice were anesthetized with diethyl ether and
transcardially perfused with PFA solution (4% paraformaldehyde,
4% sucrose in sodium phosphate buffer pH 7.5) and then with
Bouin’s solution (71% saturated picric acid [v/v], 24% formalin
[v/v], and 5% acetic acid [v/v], adjusted to pH 4.0 with sodium
hydroxide). The brains were then removed, fixed with original
Bouin’s solution for 3 days, and embedded in paraffin.
All procedures involving animals and their care were carried out
in accordance with the directives of RIKEN’s Institutional Animal
Care and Use Committee.
RNA extraction
Total RNA was purified using the RNeasy mini kit (Qiagen) and
RNeasy Lipid Tissue Midi kit (Qiagen) according to manufactur-
er’s instructions. The quality of the extracted RNA was confirmed
with Agilent 2100 Bioanalyzer.
Microarray
Five hundred nanogram of total RNA was amplified using the
Illumina TotalPrep RNA Amprification Kit (Ambion), according
to manufacturer’s instructions. cRNA was hybridized to Illumina
Mouse Sentrix-6 Expression BeadChip Ver.1, according to
standard Illumina protocols. Chips scans were processed using
Illumina BeadScan and BeadStudio software packages and
summarized data was generated in BeadStudio (version 3.1). Data
was quantile normalized using Lumi and B-statistics were
calculated using Limma (both R packages in Bioconductor)
[19,20]. Meosthelial tissue gene expression was compared pairwise
against each other tissue, and only genes where the B-statistic was
greater than 0 for all cases and the average expression in the
mesothelial tissue was greater than 2 fold for all other tissues was
the expression considered mesotheial specific. All microarray data
is MIAME compliant and the raw data has been deposited in a
MIAME compliant database (GEO (ID pending)).
qRTPCR
qRTPCR was carried out as described previously [21]. Primers
used are listed in Table S1. Primers for human MSLN were from
Jirsova et al [22], all other primers were designed in house.
In situ hybridization (ISH)
ISH was carried out using PCR generated probes with
FANTOM1 and FANTOM2 cDNA clones or genomic DNA as
templates (Table S2). ISH was carried out as described previously
[23].
Human total RNA samples
Primary cells or RNA were purchased: Mesothelial cells–
(Zenbio, Cat: F-MES-F), small airway epithelial cells (Lonza, Cat:
CC-2547), lung fibroblasts (Cell applications, Cat: CA506-R10f),
alveolar epithelial cells (Sciencell, Cat: SC3205), bronchial
epithelial cells (Sciencell, Cat: SC3215), bronchial smooth muscle
cells (Sciencell, Cat: SC3405), tracheal smooth muscle cells
(Sciencell, Cat: SC3415), retinal pigment epithelial cells (Sciencell,
Cat: SC6545) and urothelial cells (Sciencell, Cat: SC4325). The
cell lines (ACC-MESO-1, ACC-MESO-4 [24], LC-1F, EBC-1,
LU65, Lu99, PC-14, A549, Lu-134-A, LK-2, IA-5, T3M-10,
HeLa, OS-RC-2, JMSU1, TGBC2TKB, TGBC18TKB, A431,
Kato III and WERI-Rb-1) were provided by the RIKEN BRC
through the National Bio-Resource Project of the MEXT, Japan.
The additional mesothelioma cell lines were purchased from the
American type culture collection (NCI-H28, NCI-H226, NCI-
H2052, NCI-H2452 [25]) and the European Collection of Cell
Cultures (Mero-14, Mero-25, Mero-41 [26], Mero-48a, Mero-82,
Mero-83, Mero-84, Mero-95 [27], No36, ONE58 [28]). Total
RNA was prepared using QIAGEN miRNeasy columns (Cat:
LRRN4 and UPK3B as Mesothelial Markers
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RNA was purchased from Ambion (Cat: AM6000).
Immunostaining
Antibodies against synthetic peptides from UPK3B, NKAIN4
and LRRN4 were ordered from IBM as a custom service.
Immunostaining was carried out as described previously [29,30].
Results
Identification of mesothelial markers in mouse
Two sources of mesothelial tissue were dissected from 7 week
old C57/BL6 mice. Total RNA was extracted from peritoneal
mesothelium and a pool of pleural and pericardial mesothelium.
Triplicate gene expression analysis was carried out using illumina
microarrays on the mesothelium samples and unrelated tissue
RNAs (adipose, bladder, heart, liver, lung, skeletal muscle). Data
was normalized using the Lumi [19] package of bioconductor and
differential gene expression between the mesothelium and other
tissues was determined using B-statistics in the Limma [20]
package. Peritoneal mesothelium or the pleural/pericardial pool
was compared against each of the tissues separately. Only probes
that showed significance (B-statistic .0 and at least 2 fold higher
expression) in all comparisons (ie mesothelium vs heart, mesothe-
lium vs liver etc.) were considered putative mesothelium specific
markers. 460 probes (corresponding to 311 loci) passed this test as
being over-expressed in at least one of the mesothelium sources
compared to all the other tissues (Table 1, Table S3).
Surprisingly only 48 of these were significant for both mesothelium
sources. 223 were only over-expressed in the peritoneal mesothe-
lium samples and 45 were only over-expressed in the pleural/
pericardial mesothelium samples. Of the 48 genes whose
expression was enriched in both mesothelial sources seven were
previously associated with the mesothelial lineage or mesothelioma
(Aldh1a2 [31], Crip1 [32], Has1 [33], Prrx2 [34], Upk3b [35],
Wnt2b [36], and Wt1 [37]).
Interestingly Msln a previously reported marker of the
mesothelial lineage was only found to be significantly more highly
expressed in the peritoneal mesothelium and not in the pleural and
pericardial sample. For the genes enriched in only one type of
mesothelium we found separate classes of genes involved in
immune response. In the peritoneal only list, CD34 was 4 fold
higher expressed than in other tissues, and eight of the known
defensins were also enriched (11–200 times that of any other
tissue). However in the pleural + pericardial mesothelium there
was enrichment for immunoglobulin heavy and light chains (2.3–
76 times that of any other tissue) suggesting possible B or plasma
cell contamination. This suggests different sets of hematopoietic
cells are associating with the mesothelium from different locations.
To further investigate the gene sets we carried out gene
ontology analysis using the GOstat tool [38]. There was no gene
ontology enrichment for the genes highly expressed in the pleural/
pericardial mesothelium, but the list of genes expressed in both
mesothelial tissues and the peritoneal only samples were enriched
for genes involved in cell adhesion and extracellular space. The
peritoneal set was also enriched for genes involved in develop-
mental processes and multicellularity (Table S4).
qRTPCR testing of candidate markers in selected mouse
tissues
To further focus on biomarkers of mesothelium we chose a set
of 36 candidates for further confirmation by qRTPCR which were
likely to be secreted, transmembrane proteins or novel. This
included 11 of the genes enriched in both mesothelium sources, 20
genes only enriched in peritoneal mesothelium and 5 genes only
enriched in the pleural and pericardial mesothelium (Table S1).
The mesothelium specific expression of the 36 candidate
biomarkers was then tested by qRTPCR across a broader
selection of tissue RNAs (pleural + pericardial mesothelium,
peritoneal mesothelium, lung, adipose, heart, liver, brain, kidney,
thymus, spleen, intestine, testis) and 14 candidates that were still
shown to be meosthelial specific were further tested against an
additional 5 other tissues (bladder, skeletal muscle, colon, uterus,
ovary) and also against mesothelium from female mice to confirm
there were no sex specific differences. This secondary screening
Table 1. Mesothelium enriched genes identified by microarray analysis.
Mesothelium enriched genes
Both sources 2010001M06Rik , 2010107G12Rik , 4930415N12Rik , 4930455G09Rik , A730017C20Rik , A730046J19Rik , Acot11 , Aldh1a2 , Anxa9 , Aplp1 ,
Ccdc109b , Cdon , Celf4 , Chst4 , Cldn15 , Crip1 , Cybrd1 , D930030F02Rik , Dcaf12l2 , Fam70a , Flrt2 , Gpm6a , Has1 , Ildr2 , Isyna1 , Lgals7 , Lrrn4
, Nkain4 , Nxnl2 , Pkhd1l1 , Prrx2 , Rpp25 , Rspo1 , Saa3 , Serpinb2 , Sez6l , Slitrk4 , Smpd3 , Spns3 , Sulf1 , Tmem114 , Tnfrsf11b , Trem2 , Tubb2b ,
Upk3b , Vit , Wnt2b , Wt1
Peritoneal only 1110012D08Rik , 1110064A23Rik , 1500015O10Rik , 1700023F06Rik , 2410039M03Rik , 2600006K01Rik , 2900073C17Rik , 4930533K18Rik ,
5430435G22Rik , 5730409K12Rik , 6330406I15Rik , 7330423F06Rik , 9530077C05Rik , Abcg4 , Accn1 , Adamts19 , Adamts2 , Aebp1 , Agap1 ,
AI661453 , AI747448 , Ak5 , Alox15 , Anks6 , Anln , Arhgap29 , AY761184 , AY761185 , B3gnt9-ps , Bicc1 , C2 , C330020E22Rik , Cacna1g , Capn6 ,
Casp12 , Ccdc80 , Ccin , Ccrl1 , Cd109 , Cd34 , Cdh11 , Cdh3 , Cercam , Cgnl1 , Chrd , Clca6 , Clec11a , Clec4d , Clps , Col6a1 , Col6a2 , Col6a5 ,
Colec12 , Cox6b2 , Cplx2 , Cpt1c , Cpz , Crb2 , Creb3l1 , Csrp2 , Dbn1 , Dcn , Ddr1 , Defa17 , Defa20 , Defa22 , Defa23 , Defa3 , Defa5 , Defa6 , Defa-
rs1 , Dgkb , Dhrs9 , Disp1 , Dlc1 , Dlk1 , Dmrt3 , Doc2b , E330013P04Rik , Ecm1 , Efemp1 , Emilin2 , Eno2 , Enox1 , Enpp2 , Ephb6 , Espn , Etv1 ,
Fam114a1 , Fam180a , Fam184a , Fbln2 , Fbn1 , Fez1 , Fgf1 , Fgf18 , Fgf5 , Fgf9 , Fkbp10 , Fkbp14 , Fkbp9 , Flrt1 , Fosb , Gabrb1 , Gabrq , Galns ,
Galntl2 , Garnl3 , Gas6 , Ghrh , Gjb3 , Glb1l , Glt8d2 , Gm12680 , Gng4 , Gpr85 , Gria3 , Guca1a , Gxylt2 , Hif3a , Htra1 , Ifitm1 , Igfbp6 , Ikbip , Il31ra ,
Il7 , Ildr2 , Isl1 , Islr , Itln1 , Kcnab1 , Kcnip3 , Kirrel , Krt76 , Lamc3 , Leprel2 , Lgals1 , Lgals2 , Loxl1 , Loxl2 , Lrpap1 , Ltbp3 , Man2b2 , Mapk4 , Mdk ,
Mfap5 , Miat , Mmp16 , Mmp23 , Mmp24 , Msln , Mtmr11 , Muc13 , Muc16 , Muc2 , Nbl1 , Ndrg1 , Neo1 , Nfkbiz , Nid2 , Ninl , Nkx2-3 , Nlgn1 ,
Nrxn2 , Nxph1 , Oasl2 , Olfml2b , Olfr1036 , Pcolce , Penk , Piwil2 , Plat , Plekha4 , Prg4 , Ptgis , Rassf2 , Rcn3 , Reg3b , Rnf112 , Rtn1 , Scg5 , Scrn1 ,
Selp , Selv , Sema5a , Serpinh1 , Sertad4 , Sfxn3 , Sgsm2 , Slc1a7 , Slc23a3 , Smpd3 , Smpdl3b , Snord123 , Sorcs1 , Sox8 , Spink3 , Ssbp3 , Stag3 ,
Steap2 , Stra6 , Sulf1 , Sv2a , Svs5 , Tmem119 , Tmem151a , Tmem98 , Tnxb , Trim9 , Tro , Ttll12 , Ttyh1 , Tulp2 , Upk3b , Vasn , Vat1l , Vmn2r26 ,
Wasf1 , Wnt6 , Zbtb7c , Zbtb8a , Zfp185 , Zg16
Pleural + pericardial
only
1190002F15Rik , 2810417H13Rik , A530032D15Rik , A530050N04Rik , AB124611 , AI324046 , Aurkb , B230209E15Rik , Bfsp2 , Btg3 , Calcb , Csprs ,
Cxcl13 , Cybrd1 , Dntt , Expi , Fcna , Gng13 , Gpr176 , Hist1h2an , Igfbp5 , Kif22 , Oosp1 , Plac1l , Prss16 , Rag1 , Rilpl2 , Sdc3 , Sema3d , Serpina3b ,
Slc2a6 , Spo11 , Stac2 , Tbata , Tm4sf5 , Tnfrsf17 , Uhrf1 , Xpnpep2 , Zbtb32
Note: Gene names in bold have been previously associated with mesothelioma or the mesothelial lineage.
doi:10.1371/journal.pone.0025391.t001
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original identified in both tissues and 9 identified in peritoneal
only). The top 10 most mesothelial specific of these were then
chosen for further screening by in-situ hybridization.
In-situ hybridization of 10 candidate biomarkers
Of the 10 candidate biomarkers identified in the study, several
have previously been associated with the mesothelial lineage or
mesothelioma, these include the prototype mesothelial lineage
marker mesothelin (Msln)[15] and others such as uroplakin
3B(Upk3b) [35], prostaglandin I2 (prostacyclin) synthase (Ptgis)
[39] and insulin-like growth factor binding protein 6 (Igfbp6) [40].
The remaining six, leucine rich repeat neuronal 4(Lrrn4), Na+/
K+ transporting ATPase interacting 4(Nkain4), proteoglycan
4(Prg4), matrix metallopeptidase 23(Mmp23), family with se-
quence similarity 180, member A (Fam180a), selectin P(Selp) have
not been previously associated with the mesothelial lineage.
Although Prg4 specifically has not been previously associated
with the mesothelial lineage, these cells are known to produce
proteoglycans to facilitate lubrication within the peritoneum [41].
In-situ hybridization was carried out across a selection of mouse
tissues including lung and heart (both with mesothelium intact),
liver, kidney, spleen, intestine, testis and thymus. For the
previously reported markers Msln, Upk3b, Ptgis and Igfbp6
mesothelial staining was observed. In addition two of the novel
markers, Nkain4 and Lrrn4 showed mesothelial staining
(Figure 1, Figure S1).
LRRN4 is a novel human mesothelial lineage marker
To confirm the specificity of these markers in human
mesothelium and mesothelioma we designed primers against
human MSLN, UPK3B, NKAIN4 and LRRN4 (Table S1) and
tested their specificity by qRTPCR against a panel of 45 human
total RNAs. The panel was selected to contain normal lung tissue,
primary cells of the lung including a range of epithelial cells,
smooth muscle cells and fibroblasts, primary mesothelial cells from
2 donors, 16 mesothelioma cell lines, 10 lung cancer cell lines and
8 unrelated cancer cell lines. Primary retinal pigment epithelial
cells and urothelial cells were also included as unrelated epithelial
cells.
First considering the primary cells, MSLN, LRRN4 and
UPK3B were detected in the primary mesothelial cells, however
LRRN4 showed the greatest specificity and was only detected in
primary mesothelial cells. MSLN and UPK3B however were less
specific and were detected in bronchial epithelial cells and alveolar
epithelial cells or retinal pigment epithelial cells and urothelial
cells, respectively (Fig. 2).
Despite this, testing the cell line panel revealed that MSLN still
appears to be a better marker of mesothelioma than LRRN4 and
UPK3B. MSLN was detected in 15 of the 16 mesothelioma lines
testedand for13 ofthesetheexpression levelwashigher than that of
the primary mesothelial cells. In the case of LRRN4 and UPK3B
the expression was only detected in 8 or 6 of the tested lines
suggesting these markers are down-regulated or lost in cancer.
Despite the higher fraction of mesothelioma lines positive for
MSLN, it does not appear to be a completely mesothelioma
specific marker as it was strongly expressed in the large cell lung
carcinoma cell line T3M-10 and moderately expressed in the lung
adenocarcinoma line PC-14. Surprisingly MSLN was also
detected at high levels in the duodenal papillotubular adenocar-
cinoma cell line TGBC18TKB and at moderate levels in the
gastric signet ring carcinoma line Kato III, bladder transitional cell
carcinoma line JMSU1, gall bladder carcinoma line TGBC2TKB
and even weakly in the ovarian epitheloid line HeLa (Fig. 2).
Finally at this stage of the screening NKAIN4 failed to validate
as a marker of human mesothelium or mesothelioma, it was most
highly expressed in primary urothelial cells and amongst the lung
associated cell types it was much more highly expressed in alveolar
and small airway epithelial cells than mesothelial cells (Fig. 2).
Immunostaining of mesothelial biomarkers in human
mesothelioma
With the aim of developing these biomarkers for diagnostic
testing in the future we set out to generate antibodies against
UPK3B, and LRRN4. Three synthetic peptides were generated for
each of the three proteins and antibodies raised in Rabbits (Figure
S2). The best antibody for each protein was then chosen for further
testing. Immunohistochemistry staining of a human epithelial
mesothelioma sample was then carried out using these antibodies
and a positive control against MSLN [29,30]. Mesothelial specific
signal was observed for all three antibodies, with a pattern similar to
that of the MSLN positive control (Fig 3). Cell surface staining was
observed for MSLN, LRRN4 and UPK3B.
Discussion
We have described a comparative functional genomics screen to
identify novel markers of the mesothelial lineage with potential for
secretion. From this screen we identified several putative
biomarkers and went on to generate antibodies against LRRN4,
and UPK3B. In terms of specificity, LRRN4 appears to be the
most specific marker of the mesothelial lineage, however when
tested across a panel of 16 mesothelioma cell lines is only detected
in 8, and down-regulated in the remaining 8 suggesting it may be
lost during tumor progression (or adaptation to cell culture). We
show that Mesothelin is detected in 15 of 16 cell lines and is
upregulated relative to primary mesothelial cells in 13.
Figure 1. In-situ hybridization images of mouse lung tissue
with pleural mesothelium intact stained for A) mesothelin, B)
uroplakin 3b, C) leucine rich repeat neuronal 4 and D) Na+/K+
transporting ATPase interacting 4. Note the mesothelial staining in
blue.
doi:10.1371/journal.pone.0025391.g001
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demonstrated that MSLN is not restricted to mesothelium or
mesothelioma. In normal primary lung associated cells MLSN is
detected at a higher level in bronchial epithelial cells than
mesothelial cells. In tumor cell lines, expression was detected in
mesothelioma cell lines, but was also expressed at similar levels in a
large cell lung carcinoma, duodenal papillotubular adenocarcinoma,
signet ring carcinoma, transitional cell carcinoma and gall bladder
carcinoma. Weak expression in HeLa cells was also observed, which
is consistent with a list of biomarkers reported as upregulated in
cervical cancer [42]. MSLN is also upregulated in other cancers
including ovarian cancer, and pancreatic ductal adenocarcinoma
[43] and in its original description, soluble mesothelin was found to
be a serum marker for ovarian cancer [17]. This has implications for
the MESOMARK [12,13] kit for detection of soluble mesothelin as
other tumor types including some lung cancers with similar
presentations may produce soluble mesothelin.
Regarding the other two markers. UPK3B has been reported
previously as a marker of the mesothelial lineage [35]. However as
its name suggests it is also expressed in urothelial cells and we also
find strong expression in retinal pigment epithelial cells. LRRN4
however has not been previously associated with mesothelioma or
the mesothelial lineage. LRRN4 (also known as NLRR4 and
C20orf75) is a leucine rich repeat protein that was originally
identified as a neuronal protein involved in long term memory
formation [44], interestingly in this publication they note strong
expression in the lung and ovary, similar to the pattern for
mesothelin. Although LRRN4 has not been associated with
mesothelioma it has been shown previously to be regulated in
response to acute lung injury [45] and in Chronic Obstructive
Pulmonary Disease (COPD) [46] suggesting it may play a role in
response to lung damage. It is also upregulated in the adipose of
Mif knockout mice [47]. MIF (macrophage migration inhibitory
factor) is implicated in COPD [48] and is a cytokine involved in
maintenance of proinflammatory response in macrophages [49]. It
is hypothesized that there is a link between asbestos exposure,
chronic inflammation and mesothelioma [50] however whether
there is any significance in this link is unclear.
The observation that LRRN4 is highly expressed in the primary
mesothelial cells, is lost in 8 of the mesothelioma cell lines and is
Figure 2. Expression of A) MSLN, B) LRRN4, C) UPK3B, D) NKAIN4 across a panel of primary human cell types and cancer cell lines
measured by qRTPCR.
doi:10.1371/journal.pone.0025391.g002
Figure 3. Immunohistochemisty of a human epithelial mesothelioma stained with antibodies against MSLN, LRRN4, UPK3B.
doi:10.1371/journal.pone.0025391.g003
LRRN4 and UPK3B as Mesothelial Markers
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There appears to be no correlation between mesothelioma
subtypes (our collection included 7 epitheloid, 8 sarcomatoid
and 1 biphasic type cell line). Together these data paint a picture
of MSLN as a less lineage specific marker that is upregulated in
cancer to promote proliferation and migration of tumor cells [51],
while LRRN4 and UPK3B are more specific lineage markers that
provide no competitive advantage to the tumor so can be lost
during tumor progression. With this in mind it may be of interest
to consider whether loss of LRRN4 or UPK3B expression
correlates with later stage and poorer prognosis, but is beyond
the scope of the current manuscript.
In conclusion, we identified 311 putative markers of the
mesothelial lineage including 48 that were found in pleural,
pericardial and peritoneal mesothelium (it is yet to be shown
whether they are also expressed in the other rare mesothelial
populations at the tunica vaginalis and tunica serosa uteri). We
go on to demonstrate that polyclonal antibodies against two of
these, LRRN4 and UPK3B react with human mesothelioma
tissue localised to the plasma membrane. With this in mind we
are currently exploring the development of LRRN4 ELISA
based assays for detection of mesothelioma antigens in patient
body fluids.
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